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Abstract
Objectives: This study evaluates the safety, principal feasibility and restoration potential of laser-supported CD133+
intramyocardial cell transplantation in patients with ischemic cardiomyopathy.
Methods: Forty-two patients with severe ischemic cardiomyopathy (left ventricular ejection fraction (LVEF) .15% and ,
35%) were included in this prospective multicenter phase I trial. They underwent coronary artery bypass grafting (CABG)
with subsequent transepicardial low-energy laser treatment and autologous CD133+ cell transplantation, and were followed
up for 12 months. To evaluate segmental myocardial contractility as well as perfusion and to identify the areas of scar tissue,
cardiac MRI was performed at 6 months and compared to the preoperative baseline. In addition, clinical assessment
comprising of CCS scoring, blood and physical examination was performed at 3, 6 and 12 months, respectively.
Results: Intraoperative cell isolation resulted in a mean cell count of 9.761.2610
6. Laser treatment and subsequent CD133+
cell therapy were successfully and safely carried out in all patients and no procedure-related complications occurred. At 6
months, the LVEF was significantly increased (29.761.9% versus 24.661.5% with p=0.004). In addition, freedom from
angina was achieved, and quality of life significantly improved after therapy (p,0.0001). Interestingly, an extended area of
transmural delayed enhancement (.3 myocardial segments) determined in the preoperative MRI was inversely correlated
with a LVEF increase after laser-supported cell therapy (p=0.024).
Conclusions: This multicenter trial demonstrates that laser-supported CD133+ cell transplantation is safe and feasible in
patients with ischemic cardiomyopathy undergoing CABG, and in most cases, it appears to significantly improve the
myocardial function. Importantly, our data show that the beneficial effect was significantly related to the extent of
transmural delayed enhancement, suggesting that MRI-guided selection of patients is mandatory to ensure the
effectiveness of the therapy.
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Introduction
While human myocardium cannot restore appropriate function
after a significant loss of cardiomyocytes due to ischemic injury [1],
all established therapeutic strategies, except heart transplantation
with limited organ availability, focus on preventing further
ischemia-induced myocardial damage. Therefore, alternative
options for patients with severe ischemic cardiomyopathy are
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8,required. Cardiac cell therapy has been repeatedly suggested as a
promising strategy to improve the myocardial function in patients
with chronic cardiac ischemia [2–4], and currently, numerous cell
types are under evaluation for their regenerative potential [1].
Bone marrow cells (BMCs) represent the most frequently used
cell type for cardiac cell therapy [5]. They can be harvested and
up-scaled easily, and their clinical use evokes no legal or ethical
issues. In this regard, CD133+ cells, a subpopulation of adult
hematopoietic progenitor cells, are a well-established cell source
and have been proven to beneficially affect chronic cardiac
ischemia [6].
In parallel, the concept of transmyocardial laser revasculariza-
tion (TMLR) has been shown to induce angiogenesis in a large
animal model of chronic myocardial ischemia [7]. In order to
create a supportive environment before intramyocardial cell
transplantation, we recently combined the concept of TMLR
and subsequent cell therapy in patients with end-stage coronary
heart disease. This therapeutic approach resulted in remarkably
increased wall contraction at the sites of TMLR and cell injection
[8]. Therefore, we hypothesized that a combined approach may
exert beneficial effects on patients with severe chronic myocardial
ischemia. Based on these results, we modified and refined laser
treatment to what we call ‘endogenous laser-induced ventricular
enhancement’ (ELIVE). This novel approach is characterized by
applying lower energies to specific areas in the heart pre-assessed
by magnetic resonance imaging (MRI) for the purpose of inducing
a supportive environment for the transplanted cells.
The present multicenter trial has been initiated to assess the
safety and feasibility of CD133+ cell transplantation following
coronary artery bypass grafting (CABG) and ELIVE in patients
with ischemic cardiomyopathy. Moreover, the potential of this
combined cell therapy approach to improve the myocardial
Table 1. Study inclusion and exclusion criteria.
Inclusion criteria
.18 years (male or female gender)
Presence of at least two vessel coronary artery disease, with at least one vessel that is not amenable to CABG (according to the angiogram). This vessel must serve an
area of viable myocardium
Global left ventricular ejection fraction .15% and ,35%
Area of interest defined as part of free left ventricular wall with reduced contractility as preoperatively shown either in ventriculography and/or MRI/CT and/or
echocardiography
Demonstration of reduced perfusion in the area of interest by cardiac MRI/CT
Signed informed consent
Exclusion criteria
Any condition that, according to the treating physician, prevents successful cell collection or application (e.g. systemic infection, puncture for cell collection impossible)
Any condition that may adversely affect the bone marrow (such as malignancy or prior irradiation to the pelvic bone)
Emergency or salvage operation defined as within 48 hours of diagnosis
Need of additional heart surgery (e.g. valve replacement)
Previous heart surgery within 6 months (excluding implantation of a pacemaker)
Mitral valve insufficiency .grade II
Evidence of left ventricular thrombus
Increased CK (.three times normal) in patients with unstable angina
End-stage renal disease defined as serum creatinine level .3.5 mg/dl, or renal replacement therapy
Concurrent active chemotherapy for cancer
Life expectancy #2 years
Clinically active infection at the time of operation
Hepatitis infection
HIV infection
Anemia
Platelet count lower than 100/nl
Sensitivity or incompatibility against used drugs or excipients (e.g. heparin, aspirin)
Pregnancy
History of ventricular arrhythmia, not controlled by medication and/or AICD (Automatic Implantable Cardioverter Defibrillator) required
History of symptomatic carotid disease (e.g. any TIA, PRIND, stroke) within the last 3 months prior to study intervention
History of bleeding diathesis
History of disseminated intravascular coagulation
Participation in other clinical trials (at least for the last 30 days)
Not able to attend follow-up as specified in the protocol
No informed consent
doi:10.1371/journal.pone.0101449.t001
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selection of patients.
Patients and Methods
Patients
Between May 2007 and December 2010, 42 patients with
severe ischemic cardiomyopathy, presenting a decreased left
ventricular ejection fraction (LVEF) .15% and ,35%, were
enrolled in our prospective phase I multicenter trial. The study
protocol for all investigational sites (Department of Cardiovascular
Surgery, University Duesseldorf; Clinic for Cardiothoracic,
Transplantation and Vascular Surgery, Hannover Medical
School; Department of Cardiac and Thoracic Vascular Surgery,
University Hospital of Schleswig-Holstein, Luebeck; Department
of Cardiac Surgery, University Heidelberg; each in Germany) was
written according to the Declaration of Helsinki and approved by
the national competent authority, the Paul Ehrlich Institute
(reference number 188/01), as well as by the involved ethics
committees. All patients gave written and informed consent to
their participation in the trial. The inclusion and exclusion criteria
for the study cohort are displayed in [Table 1]. A CONSORT
(Consolidated Standards of Reporting Trials) flow diagram
presenting the enrollment, intervention allocation, and data
analysis is shown in [Figure 1]. Three out of 42 enrolled patients
had to be excluded from the study due to the intraoperative
necessity of technical deviations from the revascularization
strategy, due to switching to an emergency operation, or due to
missing data, respectively. [Table 2] presents the preoperative
characteristics of the 39 included patients.
The EudraCT number of this study is 2005-004051-35 and the
Current Controlled Trials number is ISRCTN49998633.
Methods
The protocol for this trial and supporting TREND checklist are
available as Protocol S1 and Checklist S1.
Surgical procedure
A novel cell preparation protocol was used allowing for CABG
with simultaneous separation and laser-supported transplantation
of CD133+ cells derived from autologous bone marrow [9].
After inhalative anesthetization, patients underwent puncture of
the iliac crest to aspirate an average volume of 281.967.4 ml bone
marrow. Afterwards, the left internal thoracic artery and a great
saphenous vein were prepared. The installation of extracorporeal
circulation was followed by CABG with intermittent application of
Calafiore blood cardioplegia.
Simultaneously, by using a CliniMACS cell separation system
with a closed circuit (Miltenyi Biotech Inc., Bergisch Gladbach,
Germany), CD133+ cells were isolated from the collected bone
marrow. Due to considerations in terms of short handling time in
parallel to the operation and highest possible cell vitality, the cell
isolation was conducted in immediate vicinity of the operation
theater under a separate clean laminar flow bench, which was
approved by the Paul Ehrlich Institute. Quality analyses of the cell
product were conducted by fluorescence-activated cell sorting
measurements.
Following coronary artery reperfusion, the areas of hibernating
myocardium technically not amenable to bypass grafting, which
had been preoperatively selected by MRI and coronary angiog-
raphy, were treated by creating an average number of 20.460.8
transmyocardial laser channels (CO2 Heart Laser, PLC Medical
Systems Inc., Milford, USA). The separated autologous CD133+
BMCs (9.761.2 610
6) were injected into these pretreated
myocardial regions by the operating surgeon. Finally, the heart
was weaned from cardiopulmonary bypass and the patient was
Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram presenting the enrollment, intervention allocation,
and data analysis of the study.
doi:10.1371/journal.pone.0101449.g001
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was 296.3649.8 min.
An overview of the simultaneous procedures of surgery and cell
preparation is displayed in [Figure 2].
Study endpoints
The primary composite endpoint of the present prospective
trial, assessed at 3 months after surgical treatment, was the safety
of the cell transplantation procedure, defined as the occurrence of
major adverse cardiac or cerebrovascular events (MACCE:
cardiac-related death, myocardial infarction, urgent or elective
percutaneous coronary intervention, stroke, or transitory ischemic
attack) or one of the following adverse events: secondary mitral
valve damage or hospitalization for any adverse event thought to
be related to cardiac function by the investigator.
The secondary endpoints comprised the above mentioned
composite endpoint at 6 and 12 months as well as the following
endpoints after 3, 6 and 12 months: adverse cardiac events,
severity of angina as assessed by reduction of classes in the CCS
grading scale, MRI-evaluated regional cardiac function and
quality of life in comparison to baseline values.
Perioperative examinations and follow-up
Cardiac MRI was used to evaluate segmental myocardial
contractility as well as perfusion and to identify the areas of scar
tissue preoperatively and 6 months after surgery. Data were
pseudo-anonymized and analyzed in a blinded manner on a 1.5
Tesla MRI scanner (Avanto, Siemens, Forchheim, Germany)
using a 17 myocardial segments system. While assessment of the
global ejection fraction was part of the prospective trial, the
segmental analyses were conducted separately. Qualitative region-
al cardiac function analyses were conducted on steady-state free
procession cine images acquired in short axis views. After
administration of 0.2 ml/kg body weight gadolinium–based
contrast agent, perfusion imaging was performed during the first
pass using a T1-weighted fast gradient echo sequence in three
short axis imaging planes representing the basal, midventricular
and apical myocardial segments. After administration of additional
0.2 ml/kg contrast material, delayed enhancement images were
acquired after a delay of 10 minutes using an inversion-recovery
gradient echo sequence. In the preoperative sequences, the
amount of transmural delayed contrast agent enhancement as
well as the percentaged number of segments with hibernating
myocardium (hypokinetic or akinetic areas with perfusion deficit
and lack of late enhancement) were determined. In case of
contraindications against MRI (n=3), cardiac computed tomog-
raphy was conducted on a 64-row multidetector-CT (Somatom
Sensation Cardiac, Siemens Healthcare, Forchheim, Germany).
After an initial scout image and a timing bolus scan at the level of
the aortic root with 20 ml of iodinated contrast agent (iomeprol,
400 g/cm
3, imeron 400, Bracco Imaging, Konstanz, Germany),
an 80 ml bolus of contrast agent was power-injected at 5 ml/s
followed by a 40 ml bolus of saline chaser. A retrospective ECG-
gated volume dataset was acquired with 64 mm 6 0.6 mm
collimation, a gantry rotation time of 330 ms, a pitch of 0.2, tube
voltage of 100–120 kV (weight-based nomogram), and a tube
current of 312–370 mAs/rotation (scout-based automatic refer-
ence tube current selection–CareDose 4D, Siemens, Germany).
To measure global functional parameters, axial 1.5 mm multi-
phase images were analyzed using commercially available software
(Syngo Argus, Siemens, Germany).
Table 2. Preoperative patients’ characteristics.
Age (y) 6661.4
Male (%) 84.6
BMI (kg m
22) 2960.8
Arterial hypertension (%) 89.7
Diabetes mellitus type II (%) 51.3
PAVD (%) 23.1
COPD (%) 10.3
Renal failure (%) 17.9
Previous myocardial infarction (%) 56.4
Previous coronary intervention (%) 25.6
Redo operation (%) 10.3
BMI = body mass index; COPD = chronic obstructive pulmonary disease; PAVD = peripheral arterial vessel disease.
doi:10.1371/journal.pone.0101449.t002
Figure 2. Surgical timeline of simultaneous CD133+ cell
isolation and CABG with subsequent laser treatment(ELIVE)-
supported cell transplantation. ELIVE, endogenous laser-induced
ventricular enhancement.
doi:10.1371/journal.pone.0101449.g002
Laser-Supported CD133+ Cell Therapy in Ischemic Cardiomyopathy
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e101449Canadian Cardiovascular Society (CCS) grading was performed
preoperatively as well as after 3, 6 and 12 months. Physical
examinations, blood serum level analyses and electrocardiography
were conducted preoperatively, after 12, 24 and 48 hours and at
all follow-up examinations (3, 6 and 12 months). All adverse events
were documented during the whole follow-up, were classified as
MACCE if indicated, and their relationship to the cell therapy
procedure was evaluated. In order to assess the quality of life, the
Seattle Angina Questionnaire (SAQ) was used.
Statistics
Statistical analysis was performed with R version 2.15.1, and
with SPSS version 20.0.0 (IBM, New York, USA). Descriptive
statistics were calculated and are presented as mean values 6
standard error of the mean for all continuous variables.
For direct comparisons of groups with continuous variables,
paired or unpaired t-tests with or without Welch’s correction were
applied, as indicated. Regarding categorial variables, pairwise
Fisher’s exact tests were conducted. The blood serum levels at
different time points were compared with each other by means of
ANOVA with Tukey’s posthoc test. The impact of preoperatively
extensive transmural delayed enhancement and hibernating
myocardium on the postoperative increase of LVEF was examined
by a linear regression analysis. For all analytical statistics, p values
,0.05 were assumed to indicate significance.
Results
Safety and feasibility
CD133+ cell isolation. The intraoperative isolation of
CD133+ BMCs was successfully conducted in all patients. Flow
cytometry analyses revealed the average number of transplanted
cells to be 9.761.2610
6, exhibiting a vitality of 93.260.9% and a
purity of 82.662.3%.
Clinical outcome. Two patients suffered from severe adverse
events which had to be classified as primary endpoint events: One
patient developed a multi organ failure and died within the first 48
postoperative hours due to a hyperkalemia-related electromechan-
ical dissociation, and another one had a severe septic shock with
metabolic disorder and final ventricular fibrillation after 72 days.
None of these adverse events was related to the cell therapy
procedure. In another patient, which was an early drop-out due to
emergency reconstruction of the mitral valve during the initial
operation, a serious adverse event with possible relationship was
observed and classified as serious adverse reaction by the
coordinating investigator during the quality assurance procedure.
In this patient, a sudden cardiac death occurred after drop-out,
which can be seen as a typical consequence of the underlying
disease.
Only one patient had a secondary endpoint event when dying of
presumably sudden cardiac death within the first 6 months.
Thorough assessment revealed no relationship to the cell therapy.
After 12 months, no additional endpoint event had occurred,
resulting in a total of three patients with endpoint events at month
12 [Table 3].
The CCS grading scale analysis revealed a significant decrease
of the severity of angina after the surgical procedure. After 3, 6
and 12 months, the percentage of patients with CCS grades #II
was 100% versus 35.1% preoperatively (p,0.0001 at each time
point) [Table 4]. Analyzing the physical limitation scale of the
SAQ, we found a significant increase of quality of life during the
follow-up (40.261.4 after 3 months, 40.961.5 after 6 months,
43.761.0 after 12 months; each with p,0.0001 versus 28.461.5
preoperatively) [Figure 3].
Electrocardiography did not reveal any postoperatively new q-
wave myocardial infarction or ST segment elevation. The blood
serum level analyses during the follow-up revealed results as
expected after cardiac surgery in patients with ischemic cardio-
myopathy [Table 5].
Myocardial function
Left ventricular contractility. The LVEF significantly
improved after surgery (29.761.9% versus 24.661.5% with
p=0.004 at 6 months). Moreover, the left ventricular enddiastolic
volume was decreased (264.2616.9 ml versus 284.4614.8 ml with
p=0.01). After 6 months, the total number of hypokinetic
segments was reduced (5.960.9 versus 6.660.9 preoperatively,
p=0.296), as well as the number of akinetic segments (3.260.5
versus 4.960.7 preoperatively, p=0.014).
Prediction of the benefit of the CD133+ cell therapy. We
aimed at examining whether patients with extensive myocardial
scars profited less from the therapy. Interestingly, the preoperative
global LVEF value was not correlated with the postoperative
increase of the LVEF (slope 0.360.4 and r
2=0.02 with p=0.540)
[Figure 4A]. Therefore, we conducted more sophisticated regional
analyses of myocardial function and viability based on a 17
myocardial segments model. In that context, we determined the
correlation of the preoperative amount of transmural delayed
contrast agent enhancement with the increase of the LVEF after 6
months. A linear regression analysis revealed a negative correla-
tion of the two parameters (slope 21.860.7 and r
2=0.25 with
p=0.024) [Figure 4B]. Moreover, transmural delayed enhance-
ment in more than three myocardial segments resulted in
significantly lower increase of the LVEF after 6 months, as
compared to patients with three or less affected segments
(1.061.4% versus 10.064.3% with p=0.042) [Figure 5]. A larger
percentaged area of hibernating myocardium in the preoperative
MRI was accompanied by a higher increase of the LVEF after 6
months. However, this correlation was not found to be significant
(slope 0.260.2 and r
2=0.1 with p=0.237) [Figure 4C]. Patients
with more than 15% hibernating myocardium showed a larger
postoperative increase of the LVEF than patients with less than
15% hibernating myocardium (9.264.8% versus 2.062.0% with
p=0.063).
Table 3. Endpoint events.
Primary endpoint Secondary endpoint
I) Multi organ failure (48 hours)
II) Septic shock (72 days)
III) Sudden cardiac death (6 months)
doi:10.1371/journal.pone.0101449.t003
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Safety and feasibility
The primary aim of the present multicenter trial was the
examination of a combined therapeutic approach for patients with
end-stage ischemic heart failure. This is the first clinical study of
CABG with simultaneous, laser treatment(ELIVE)-supported
CD133+ cell transplantation, and the results proved our protocol
to be feasible and safe. Neither any CD133+ cell processing
failure, nor any serious adverse events which had to be assessed as
at least probable procedure-related events were observed. Two
serious adverse events with possible procedure-related relationship
were reported in the trial, however, in one patient re-assessment
after the follow-up revealed no relationship, and in the other
patient, a sudden cardiac death occurred after drop-out, which
can be seen as a typical consequence of the underlying disease.
While in most previous BMC transplantation studies, the bone
marrow was harvested pre-interventionally, the approach of the
present study features intraoperative cell isolation and processing
without the necessity of additional anesthetization, cultivation or
storage of the cell product, significantly simplifying processing
logistics [10]. Albeit using a time-optimized accelerated procedure
protocol, the procedure resulted in a high-quality cell product in
terms of purity as well as vitality. This approach was presented for
the first time in a small cohort study in patients with intractable
ischemic heart disease who received laser treatment and CD133+
cell transplantation [11].
The rationale of conducting ELIVE before cell transplantation
was to create an environment by which survival, growth and
potential function-restoring effects of the injected cells may be
supported, especially by inducing angiogenesis. In porcine models
of chronic myocardial ischemia as well as acute myocardial
infarction, laser treatment was previously shown to improve local
angiogenesis as well as the survival of administered mesenchymal
stem cells into the infarcted region [12–15].
Clinical outcome
As a result of the combined surgical procedure, the CCS grades
were significantly reduced and the quality of life was improved 3, 6
and 12 months after surgery. Both effects may partially be
attributed to coronary revascularization, which was performed in
all these patients. However, all study patients suffered from severe
heart failure with ischemic areas of viable myocardium which were
technically ineligible for CABG. Nevertheless, we found a
significant decrease of clinical ischemia symptoms with no residual
angina after 6 months. While many studies have shown short-term
improvement of symptoms after laser treatment in patients with
refractory angina, controversial data have been reported on the
Table 4. CCS grading before and after cell therapy.
CCS grading Pre (n) 3 months * (n) 6 months * (n) 12 months * (n)
#II 13 33 27 25
.II 24 0 0 0
At all postoperative time points, 100% of the patients showed CCS grades #II (versus 35.1% preoperatively). Pre, preoperatively; * p,0.0001 versus pre.
doi:10.1371/journal.pone.0101449.t004
Figure 3. Quality of life after cell therapy. At all postoperative time points, the physical limitation score of the Seattle Angina Questionnaire
(SAQ) was significantly improved (40.261.4 after 3 months, 40.961.5 after 6 months, 43.761.0 after 12 months, versus 28.461.5 preoperatively). Pre,
preoperatively. Separated values, outliers included in the statistical analysis. Asterisk, p,0.0001 versus pre.
doi:10.1371/journal.pone.0101449.g003
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functional benefit beyond 18 month after TMLR only [16,17].
These findings underline single laser treatment to be an end-stage
option for patients with severe heart failure. For this reason,
combined approaches utilizing TMLR and cell therapy have been
proposed aiming at the cellular component to beneficially affect
the diseased myocardium in the long-term, predominantly by
paracrine effects on resident cardiac cells. Among other cell lines,
CD133+ and CD34+ cells were reported to reduce the CCS
grades in patients with ischemic cardiomyopathy [2,18]. Com-
bined laser and BMC therapy also exerted positive effects on
refractory angina [19].
In our study, no patient died due to cardiac reasons, although
all patients were initially suffering from end-stage ischemic
cardiomyopathy. BMC treatment in patients with chronic
ischemia was previously reported to reduce the mortality even 5
years after intracoronary cell delivery [20]. For patients with acute
myocardial infarction, the BOOST trial could not confirm the
superiority of intracoronary BMC transplantation in terms of
mortality after 5 years [21]. However, large trials with long follow-
up periods are necessary in order to further evaluate the potential
of cell therapy to improve the survival of patients with chronic
ischemia.
Improvement of myocardial function
The combined approach of ELIVE and CD133+ cell therapy in
CABG patients of the present trial beneficially affected the left
ventricular function in severe ischemic cardiomyopathy. In a
previous study, Stamm et al. described a significant postoperative
improvement of the LVEF 6 months after CD133+ cell
transplantation in CABG patients with moderately reduced LVEF
[10]. However, the same group reported that with regard to the
LVEF, combined CABG and cell therapy were not superior to
single CABG beyond 6 months after surgery [22]. In fact, they
found a LVEF ,40% and a time period of 7 to 12 weeks between
myocardial infarction and surgery to be predictors of an
improvement of the LVEF of at least 5%. Similarly, intracoronary
infusion of CD133+ cells in patients with chronic myocardial
infarction was reported to improve the left ventricular function [4].
In opposite to these studies on CD133+ cells, the transplantation
of unfractionated BMCs in chronically ischemic myocardium
failed to show functional improvement in several studies [3]. One
year after having injected mononuclear BMCs in the infarction
border zone in CABG patients with a LVEF #45%, the
investigators could not find a beneficial effect of cell therapy on
the LVEF or the wall thickening measured by MRI, when
compared to the control group with CABG only [23]. However,
when analyzing the myocardial scar size in the cell administration
areas, a significant decrease was observed in the BMC group. A
study comparing intramyocardial as well as intracoronary BMC
application in CABG patients with CABG only did not reveal any
significant improvement in several parameters of global and
regional cardiac function after 6 months, whereas intramyocardial
injection showed a remarkable trend towards reduced scar size as
well as improvement of the LVEF, when compared with
intracoronary injection or controls [24].
Trials examining intracoronary transplantation of BMCs in
patients after acute myocardial infarction and successful interven-
tional revascularization resulted in controversial functional results:
Two years after intracoronary cell administration, the baseline-
adjusted LVEF in the BMC group of the AMI-REPAIR trial was
reported to be significantly improved versus control patients [25].
After an initial increase of the LVEF in the BMC group of the
BOOST trial (6 months), Meyer et al. observed no significant
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61 months, whereas the baseline LVEF values were higher than in
the AMI-REPAIR trial [21]. The SWISS-AMI trial aimed at
determining the optimal time point of BMC administration after
acute myocardial infarction. However, neither by early (5–7 days)
nor by late (3–4 weeks) intracoronary cell therapy, an improve-
ment of the LVEF could be achieved after 4 months [26].
Intracoronary cell application in the BONAMI trial resulted in
enhanced myocardial viability after 3 months, measured by single-
photon-emission computed tomography [27]. However, the LVEF
was not increased as compared to control patients. A very similar
study design was applied to the HEBE trial and the TIME trial,
which likewise did not result in an improvement of the LVEF after
4 and 6 months, respectively [28,29]. As opposed to the
implications of the BONAMI trial, no post-interventional reduc-
tion of dyskinetic myocardial segments was observed. Patients in
the cell therapy and the control group of the BONAMI trial had a
mean baseline LVEF of 35.6% and 37.0%, respectively, while in
the HEBE trial, the values accounted for 43.7% and 41.7% in the
therapy groups and 42.4% in the control group.
In a previous publication on the technical approach of
combined CABG, laser treatment and CD133+ cell therapy, we
have reported exemplary LVEF data which had been measured by
2D echocardiography in patients having been included in the
study at early time points [9]. This subset of patients even showed
a LVEF increase from 25% preoperatively to 40% after 6 months.
Analysis of the echocardiography-based LVEF of all study patients
at the end of the trial resulted in an increase from 27.760.9%
preoperatively to 37.661.4% after 6 months (p,0.001). Although
the final study evaluation based on MRI could not confirm this
extent of functional improvement, still a significant increase in
LVEF was observed (30% after 6 months vs. 25% preoperatively).
Besides the fact that the previous publication had included only
some of the study patients which had already been followed-up at
that time point, the evaluation method may explain the different
results. While 2D echocardiography data can be observer-
dependent to a large extent, MRI is regarded to be the gold
standard for global as well as regional functional evaluation of
ischemic myocardium [30–32].
Adequate selection of patients undergoing cell therapy
The controversial clinical reports on functional improvement by
cell therapy of ischemic myocardium raise the question of
adequate selection of patients undergoing myocardial cell therapy.
In particular, preoperative parameters which are correlated to the
post-therapeutic improvement of myocardial function in ischemic
cardiomyopathy are required.
With regard to patients’ selection, Yerebakan et al. had reported
that patients with a LVEF ,40% profit more from CD133+ cell
transplantation [22]. In the present study cohort of patients with
LVEF values ,35%, the preoperative LVEF did not influence the
functional benefit of the cell therapy. Especially in terms of severe
chronic ischemia with large myocardial scar tissue areas, more
sophisticated examinations seem to be necessary to select the right
patients for cell therapy.
Moreover, adequate sites of injection of the cell suspension have
to be chosen. In order to address both aspects, we determined all
myocardial segments with transmural delayed contrast agent
enhancement in the preoperative MRI measurements, indicating
myocardial scar tissue [33]. These analyses revealed that patients
with less increase of the LVEF after surgical cell therapy had larger
Figure 4. Preoperative indicators for the improvement of the LVEF. While the preoperative global LVEF values were not correlated with the
postoperative increase of the LVEF (A), we found an inverse correlation of the preoperative amount of transmural delayed enhancement (TDE) with
the postoperative increase of the LVEF (B). The association of a preoperatively larger percentaged area of hibernating myocardium with a higher
increase of the LVEF was not statistically significant (C).
doi:10.1371/journal.pone.0101449.g004
Figure 5. Transmural delayed enhancement (TDE) and the
postoperative increase of the LVEF. TDE in more than three
myocardial segments (at screening MRI) resulted in significantly less
increase of the LVEF after 6 months, as compared to patients with three
or less affected segments (1.061.4 versus 10.064.3, p=0.042).
doi:10.1371/journal.pone.0101449.g005
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MRI. A total number of more than three out of 17 segments with
transmural delayed enhancement was shown to be significantly
associated with a less beneficial functional outcome. Therefore, the
extent of transmural delayed enhancement may be used as a
preoperative predictor of the effectiveness of cell therapy in
chronically ischemic myocardium.
Limitations of the study
The present prospective study was primarily designed as a safety
and feasibility trial without control group. Thus, our combined
approach of CABG, ELIVE and cell therapy does not allow for
separately discriminating the actual effects of ELIVE and cell
therapy. However, laser treatment is strongly assumed to establish
a supportive environment for cell therapy, while the transplanted
cells may induce restoration of the myocardial function. In order
to track the in vivo fate of the administered cells and to correlate
this information with observed clinical benefits, modern imaging
techniques based on MRI or positron emission tomography should
be additionally considered in future trials [34].
Conclusions
In the present multicenter trial, we established a safe protocol of
intraoperative CD133+ cell isolation and laser-supported trans-
plantation in CABG patients with end-stage ischemic cardiomy-
opathy. This approach resulted in relief from angina and
significant improvement of quality of life as well as of the
myocardial function measured by left ventricular ejection fraction
and enddiastolic dilation. However, the beneficial results obtained
from this pilot study require further evaluation in a randomized
efficacy trial. More interestingly, we elucidated the preoperative
amount of transmural delayed enhancement to be inversely
correlated with the postoperative increase of the left ventricular
function. Thereby, MRI-guided selection of patients may be a
worthwhile tool to improve the effectiveness of laser-supported
myocardial cell therapy. In this context, large-scale studies in
patients with moderately as well as severely impaired myocardial
function are necessary to confirm adequate selection criteria for
patients undergoing cell therapy.
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